STOCK TITAN
  1. Home
  2. News
  3. RCEL

AVITA Medical Inc - RCEL STOCK NEWS

Welcome to our dedicated news page for AVITA Medical (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on AVITA Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AVITA Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AVITA Medical's position in the market.

News
AVITA Medical to Host Investor Webinar Briefing
Rhea-AI Summary
AVITA Medical, Inc. (RCEL) invites shareholders and prospective investors to attend its investor webinar briefing and presentation on December 5, 2023, highlighting a 51% commercial revenue growth in the third quarter of 2023 compared to the same period in 2022. The webinar will cover business highlights, revenue guidance, and conclude with Q&A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
conferences
-
News
AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
AVITA Medical, Inc. (RCEL, AVH) announced that CEO Jim Corbett will present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. The company is a regenerative medicine leader in first-in-class devices and autologous cellular therapies for skin restoration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences
-
News
AVITA Medical Updates Full Year 2023 Guidance
Rhea-AI Summary
AVITA Medical, Inc. (RCEL, AVH) announces an update to its full year 2023 guidance due to slower progression through the customer’s Value Analysis Committee processes. The expanded label for full-thickness skin defects is driving longer hospital approval timelines, leading to a revision of expected commercial revenue to approximately $49.5 million to $50.5 million, reflecting growth rates of approximately 45% and 48% over the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.9%
Tags
none
News
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) reported Q3 2023 financial results, including a 51% increase in commercial revenue to $13.5 million, an 84.5% gross margin, and a debt financing facility secured for up to $90.0 million. The company anticipates FDA approval for RECELL GO under the Breakthrough Device program on May 30, 2024, with plans to reach profitability in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.27%
Tags
earnings
-
News
AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe
Rhea-AI Summary
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) has entered into a distribution agreement with PolyMedics Innovations GmbH to expand its global presence to Europe. PolyMedics will be the exclusive distributor of RECELL® in Germany, Austria, and Switzerland, with potential expansion to more European markets in the future. This partnership marks the first step in AVITA Medical's strategic global expansion, leveraging PolyMedics' expertise and distribution network of over 40 global markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.45%
Tags
partnership
-
News
AVITA Medical to Announce Third Quarter 2023 Financial Results
Rhea-AI Summary
AVITA Medical to report third quarter 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
earnings
News
AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives
Rhea-AI Summary
AVITA Medical reports preliminary commercial revenue of $13.5 million for Q3 2023 and confirms full year 2023 guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
earnings
-
News
AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma
Rhea-AI Summary
AVITA Medical's RECELL® System wins Best Product for the second year in a row at the Annual Meeting of the American Association for the Surgery of Trauma (AAST). Results of the pivotal trial for full-thickness skin defects were accepted for publication in AAST's Journal of Trauma and Acute Care Surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
-
News
AVITA Medical to Present at the Cantor Global Healthcare Conference
Rhea-AI Summary
AVITA Medical to present at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
conferences
News
AVITA Medical to Participate in Upcoming Investor Conferences
Rhea-AI Summary
AVITA Medical, Inc. announces participation in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
Stock RCEL logo
AVITA Medical Inc

Nasdaq:RCEL

RCEL Rankings

#3670 Ranked by Market Cap
#166 Ranked by Stock Gains
N/A Ranked by Dividends

RCEL Stock Data

253.98M
24.81M
0.66%
28.08%
2.83%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Valencia

About RCEL

avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.